| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 57.149 | 68.832 | 84.936 | 169.967 | 88.043 | 131.986 | 441.555 | 656.889 | 843.822 | 743.450 |
| Total Income - EUR | 44.478 | 67.797 | 83.191 | 172.069 | 90.747 | 224.626 | 525.882 | 699.535 | 853.224 | 862.209 |
| Total Expenses - EUR | 75.667 | 83.089 | 91.831 | 166.618 | 102.878 | 133.051 | 394.375 | 598.132 | 738.644 | 720.812 |
| Gross Profit/Loss - EUR | -31.189 | -15.292 | -8.640 | 5.451 | -12.130 | 91.575 | 131.507 | 101.402 | 114.579 | 141.397 |
| Net Profit/Loss - EUR | -32.905 | -15.986 | -9.490 | 3.751 | -13.012 | 90.385 | 126.569 | 95.622 | 108.095 | 121.665 |
| Employees | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 6 |
Check the financial reports for the company - Nistorel Company Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 4.609 | 5.460 | 43.083 | 47.262 | 69.676 | 103.718 | 282.884 | 319.453 | 323.318 | 339.598 |
| Current Assets | 36.807 | 53.886 | 26.302 | 58.157 | 76.912 | 137.551 | 80.252 | 230.039 | 309.241 | 247.828 |
| Inventories | 29.775 | 33.240 | 9.034 | 22.507 | 31.126 | 53.985 | 43.286 | 66.344 | 93.067 | 63.189 |
| Receivables | 3.796 | 13.040 | 13.540 | 10.140 | 14.155 | 18.403 | 34.057 | 153.918 | 189.117 | 168.207 |
| Cash | 3.236 | 7.606 | 3.727 | 25.510 | 31.631 | 65.163 | 2.909 | 9.776 | 27.056 | 16.432 |
| Shareholders Funds | -35.579 | -51.202 | -59.825 | -54.976 | -66.924 | 24.730 | 146.485 | 231.279 | 338.175 | 457.950 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 76.995 | 110.548 | 129.209 | 160.395 | 213.512 | 216.539 | 216.651 | 318.213 | 294.384 | 129.476 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4621 - 4621" | |||||||||
| CAEN Financial Year |
147
|
|||||||||
Comments - Nistorel Company Srl